Vir Biotechnology, Inc. — Director's Dealing 2021

Feb 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-02-16

Reporting Person: Pang Phillip (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-16	Common Stock	M	10000	$0.855	Acquired	77277	Direct
2021-02-16	Common Stock	A	32000	$0.00	Acquired	109277	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-16	Stock Option (Right to Buy)	$0.855	M	10000	Disposed	2027-03-09	Common Stock (10000)	Direct
2021-02-16	Stock Option (Right to Buy)	$67.38	A	64000	Acquired	2031-02-15	Common Stock (64000)	Direct

Footnotes

F1: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.

F2: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.

F3: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter.